On this page
The research desk’s view
MOTS-c is listed as an optional add-on with individual menu pricing. $150 MOTS-c menu figure; supply period requires confirmation.
The listing, in detail
- Published service
- Clinical program beginning with a thirty-minute consultation
- Product/menu scope
- MOTS-c is listed as an optional add-on with individual menu pricing.
- Cost position
- $150 MOTS-c menu figure; supply period requires confirmation
- Decision condition
- Confirm exact product, individual eligibility and complete quote before a payment commitment
What the listing establishes
- MOTS-c is listed as an optional add-on with individual menu pricing.
- $150 MOTS-c menu figure; supply period requires confirmation
What it leaves unanswered
- The add-on framing changes the bill. Find out whether MOTS-c can be purchased without another program and what the consultation or membership requires. A smaller add-on price should not outrank a standalone service without counting the prerequisite.
- A provider listing does not establish individual eligibility or a clinical benefit.
What a reader can establish
True Longevity Clinic enters this comparison through a specific public listing: MOTS-c is listed as an optional add-on with individual menu pricing. The service describes clinical program beginning with a thirty-minute consultation. That gives a reader a real place to begin asking questions, while leaving the clinical decision individual. It does not independently verify the pharmacy, establish that the product is appropriate or promise access. The starting evidence guide is useful background because the body's own MOTS-c signal and an administered product answer different research questions.
Why this detail matters
The add-on framing changes the bill. Find out whether MOTS-c can be purchased without another program and what the consultation or membership requires. A smaller add-on price should not outrank a standalone service without counting the prerequisite.
The financial question to resolve
The public cost position is: $150 MOTS-c menu figure; supply period requires confirmation. The written-quote comparison separates a medication amount from the costs of the wider care relationship.
A research finding is not a personal forecast
The distinction becomes clearer in the linked research appraisal. Its setting was human HBV cohorts plus infected mouse and cell systems, and the outcomes concerned circulating peptide, viral measures and mitochondrial signaling. The people in the biomarker cohort were not a randomized MOTS-c treatment trial. That observation helps a reader ask a narrower question of True Longevity Clinic: which human outcome evidence supports the exact proposal? A scientific reason for interest is not a forecast of a personal response, and a convenient care pathway does not turn the experimental system into a patient treatment trial.
The next comparison to make
For another service model, read the next provider comparison, which concerns houston service page; the relevant offerings are explicitly waitlisted. The point is to compare the care arrangement and remaining questions, not imply the same product or endorse a clinical outcome. A service with a clearer price can still have unresolved clinical suitability; a consultation with no product guarantee can still provide useful assessment. We have not measured patient experience, support speed or the quality of a supplied preparation at either service.
Read the source
Research findings and provider statements are different evidence.
- True Longevity Clinic official product or clinical-service pageCompany website